Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) were down 6% during trading on Tuesday . The company traded as low as $4.95 and last traded at $4.99, with a volume of 240,731 shares traded. The stock had previously closed at $5.31.

A number of equities analysts have issued reports on ARGS shares. Roth Capital raised their price target on shares of Argos Therapeutics from $11.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, April 19th. Needham & Company LLC reissued a “buy” rating on shares of Argos Therapeutics in a research report on Saturday, April 23rd. Zacks Investment Research lowered shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 5th. FBR & Co reissued a “buy” rating on shares of Argos Therapeutics in a research report on Saturday, May 14th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $11.84.

The firm’s 50-day moving average is $5.94 and its 200-day moving average is $5.71. The stock’s market capitalization is $129.20 million.

Argos Therapeutics (NASDAQ:ARGS) last released its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.56) by $0.01. On average, equities research analysts anticipate that Argos Therapeutics Inc. will post ($1.74) earnings per share for the current year.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.